Tango Therapeutics (TNGX) Enterprise Value (2020 - 2026)

Tango Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$157.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 27.18% year-over-year to -$157.8 million in Q1 2026; TTM through Mar 2026 was -$157.8 million, a 27.18% increase from a year earlier, with the FY2025 full-year figure at -$112.7 million, up 56.73% from the prior year.
• Enterprise Value declined to -$157.8 million in Q1 2026 per TNGX's latest filing, from -$112.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$58.8 million in Q3 2025 and bottomed at -$449.9 million in Q1 2022.
• The 5-year median for Enterprise Value is -$216.7 million (2025), against an average of -$219.7 million.
• Biggest YoY gain for Enterprise Value was 79.98% in 2022; the steepest drop was 583.81% in 2022.
• Year by year, Enterprise Value stood at -$60.5 million in 2022, then fell by 11.08% to -$67.2 million in 2023, then slumped by 287.39% to -$260.5 million in 2024, then surged by 56.73% to -$112.7 million in 2025, then plunged by 40.03% to -$157.8 million in 2026.
• Per Business Quant, the three latest TNGX Enterprise Value figures stand at -$157.8 million (Q1 2026), -$112.7 million (Q4 2025), and -$58.8 million (Q3 2025).